Abstract: An electrode plate stacking method includes: determining, based on a first electrode plate, a conveying order of a plurality of second electrode plates, the first electrode plate being a continuous electrode plate, the plurality of second electrode plates including at least one upper electrode plate and at least one lower electrode plate, the plurality of second electrode plates being discontinuous electrode plates, and the conveying order being used for conveying the at least one upper electrode plate and the at least one lower electrode plate alternately; generating an identifier sequence for the plurality of second electrode plates based on the conveying order; and collecting first image data of each of the plurality of second electrode plates based on the identifier sequence in a process of conveying the plurality of second electrode plates in the conveying order.

Abstract: An implant delivery handle, an implant system, a delivery system and a method of use thereof are disclosed. Transmission systems in the implant delivery handle each include a lead screw, an inner tube coupling member, an outer gear and an inner gear. The outer gear rotatably engages the inner gear and is configured to drive rotation of the inner gear. The lead screw is coupled to a first inner tube (11) or a second inner tube (12) through the inner tube coupling member. The lead screw also engages the inner gear and rotates therewith to cause axial movement of the first inner tube (11) or the second inner tube (12). A transmission ratio of the outer gear to the inner gear is greater than 1.

Abstract: The present disclosure provides a testis-targeted lycopene (LYC)/ZIF-90 nanocomposite and a preparation method and use thereof, belonging to the technical field of targeted drugs. In the present disclosure, a ZIF-90 metal-organic framework (MOF) material is combined with LYC through aldol condensation; when entering areas of inflammatory response and oxidative stress response, ZIF-90 may disintegrate and collapse in a slightly-acidic environment, releasing the LYC, thereby avoiding easy oxidation of the LYC and improving a bioavailability of the LYC; in addition, the disintegrated and collapsed ZIF-90 may also be utilized by organisms, thus greatly reducing a damage to the organisms. Moreover, the LYC/ZIF-90 nanocomposite is further loaded with follicle-stimulating hormone (FSH).

Abstract: Computing architecture comprises an off-chip memory, an on-chip cache unit, a prefetching unit, a global scheduler, a transmitting unit, a pre-recombination network, a post-recombination network, a main computing array, a write-back cache unit, a data dependence controller and an auxiliary computing array. The architecture reads data tiles into an on-chip cache in a prefetching mode, and performs computing according to the data tiles; in the computing process of the tiles, a tile exchange network is adopted to recombine a data structure, and a data dependence module is arranged to process a data dependence relationship possibly existing between different tiles. According to the computing architecture, the data utilization rate can be increased, the data processing flexibility is improved, and therefore Cache Miss is reduced, and the memory bandwidth pressure is reduced.

Abstract: A method for event-triggered distributed reinforcement learning for unit commitment optimization and dispatch to solve the waste problem of unit resources includes obtaining a unit commitment optimization and dispatch model, constructing a fixed action set under preset constraint conditions, and selecting optimal power of each unit; transforming constraint conditions into projection constraints, and projecting the virtual generation power to a corresponding constraint range, to obtain actual generation power of each unit within the constraint range; calculating corresponding rewards based on cost under actual generation power of each unit without bandwidth constraints, and updating local Q values of each unit in a Q table according to Q-learning algorithms, to obtain an optimal action of each unit without bandwidth constraints; and under the constraint conditions of considering bandwidths, obtaining an optimal solution, meeting limited bandwidth constraint conditions, to the unit commitment optimization and d

Abstract: Computing architecture comprises an off-chip memory, an on-chip cache unit, a prefetching unit, a global scheduler, a transmitting unit, a pre-recombination network, a post-recombination network, a main computing array, a write-back cache unit, a data dependence controller and an auxiliary computing array. The architecture reads data tiles into an on-chip cache in a prefetching mode, and performs computing according to the data tiles; in the computing process of the tiles, a tile exchange network is adopted to recombine a data structure, and a data dependence module is arranged to process a data dependence relationship possibly existing between different tiles. According to the computing architecture, the data utilization rate can be increased, the data processing flexibility is improved, and therefore Cache Miss is reduced, and the memory bandwidth pressure is reduced.

Abstract: Systems and methods for change in language-based textual analysis are disclosed. In one embodiment, in an information processing apparatus comprising at least one computer processor, a method for change in language-based textual analysis may include: (1) retrieving, from a data source, a first document of a first type; (2) retrieving, from the data source, a second document of the first type, the second document being subsequent in time to the first document; (3) identifying changes between the first document and the second document; (4) calculating a change score based on the changes; and (5) providing the change score to a downstream system for projecting a performance of an investment associated with the first document.

Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: The invention encompasses compounds having formula I or II and the compositions and methods using these compounds in the treatment of conditions in which inhibition of PKC and PKD is therapeutically useful.

Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: The present invention provides 3-hydroxyphenyl-2,4-pyrimidinediamine compounds of formula I, as well as related compositions and methods for treating a variety of autoimmune diseases.

Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: The present invention provides 3-hydroxyphenyl-2,4-pyrimidinediamine compounds of formula I, as well as related compositions and methods for treating a variety of autoimmune diseases.

Abstract: The invention encompasses compounds having formula I or II and the compositions and methods using these compounds in the treatment of conditions in which inhibition of PKC and PKD is therapeutically useful.

Abstract: The present invention provides 3-hydroxyphenyl-2,4-pyrimidinediamine compounds of formula I, as well as related compositions and methods for treating a variety of autoimmune diseases.